Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MODIFY III pediatric bezlotoxumab trial for prevention of recurrent Clostridioides difficile infection
2017-000070-11Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Clostridioides difficile colitis (CDI) and Clostridioides difficile infection recurrence (rCDI) comparing Bezlotoxumab with Placebo (2 arms). Primary endpoint: Bezlotoxumab AUC0-inf by age cohort. Started Jul 2017; status: completed.
02
Drugs
bezlotoxumab
03
Conditions
Clostridioides difficile colitis (CDI)Clostridioides difficile infection recurrence (rCDI)
Beyond the preview
Go deeper on 2017-000070-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000070-11.